TCL Archive IDMC Recommends Halting Phase III Trial Of Onartuzumab in MET-Positive NSCLC March 28, 2014
TCL Archive Three Cancer Centers Test Targeted Therapy For Resistant Acute Myelogenous Leukemia July 26, 2002
TCL Archive Anticancer Vaccine Trials Due In Three-Four Years; Virus Research Opportunities Described July 25, 1975
